Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAN2A1 | Q16706 | 1/20 | 0.33 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20819850 | 1.00 | GBA1 (0.41) | GBA1EPHX1CTSCSLC6A2SLC6A4 | |
| SCHEMBL20819907 | 1.00 | GBA1 (0.41) | GBA1EPHX1CTSCSLC6A2SLC6A4 | |
| SCHEMBL20819950 | 1.00 | GBA1 (0.41) | GBA1EPHX1CTSCSLC6A2SLC6A4 | |
| SCHEMBL22371738 | 1.00 | GBA1 (0.41) | GBA1EPHX1CTSCSLC6A2SLC6A4 | |
| SCHEMBL20819949 | 1.00 | GBA1 (0.41) | GBA1EPHX1CTSCSLC6A2SLC6A4 | |
| SCHEMBL20819970 | 1.00 | GBA1 (0.41) | GBA1EPHX1CTSCSLC6A2SLC6A4 | |
| SCHEMBL20819969 | 1.00 | GBA1 (0.41) | GBA1EPHX1CTSCSLC6A2SLC6A4 | |
| SCHEMBL20819905 | 1.00 | GBA1 (0.41) | GBA1EPHX1CTSCSLC6A2SLC6A4 | |
| SCHEMBL20819962 | 0.83 | SLC6A3 (0.42) | SLC6A2SLC6A4SLC6A3LMNA | |
| SCHEMBL9092486 | 0.81 | GBA1 (0.46) | GBA1EPHX1MAN2A1MAN1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427539-B2 | Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia | ATROGI AB (SE) | 2022-08-30 | — | — | US | disclosed |
| US-20200277259-A1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2020-09-03 | — | — | US | disclosed |
| EP-3681862-A1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019053425-A1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277259-A1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | SLC5A1, GPR119, SLC5A2 | GBA1 695/4885EPHX1 828/4885CTSC 2088/4885 |
| US-11427539-B2 | Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia | SLC5A1, GPR119, SLC5A2 | GBA1 695/4885EPHX1 828/4885CTSC 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.